The involvement of Mts1(S100A4), a small Ca 2+ -binding protein in tumor progression and metastasis had been demonstrated. However, the mechanism by which mts1(S100A4) promoted metastasis had not been identi®ed. Here we demonstrated that Mts1(S100A4) had signi®cant stimulatory eect on the angiogenesis. We detected high incidence of hemangiomas ± benign tumors of vascular origin in aged transgenic mice ubiquitously expressing the mts1(S100A4) gene. Furthermore, the serum level of the Mts1(S100A4) protein increased with ageing. Tumors developed in Mts1-transgenic mice revealed an enhanced vascular density. We showed that an oligomeric, but not a dimeric form of the Mts1(S100A4) protein was capable of enhancing the endothelial cell motility in vitro and stimulate the corneal neovascularization in vivo. An oligomeric fraction of the protein was detected in the conditioned media as well as in human serum. The data obtained allowed us to conclude that mts1(S100A4) might induce tumor progression via stimulation of angiogenesis. Oncogene (2001) 20, 4685 ± 4695.
Introduction
Metastases are the main cause of death of cancer patients and represent the main complication in the cancer disease. The mechanisms enabling the cancer cell to metastasize remain generally obscure. Several genes were isolated as being implicated in the tumor progression and metastasis. Among them is the mts1(S100A4) gene that was isolated as a gene dierentially expressed in highly metastatic mouse mammary adenocarcinoma cells (Ebralidze et al., 1989) . Involvement of the mts1(S100A4) gene in the promotion of the metastatic disease was demonstrated by several approaches Ambartsumian et al., 1996; Davies et al., 1996; Barraclough, 1998) . The Mts1(S100A4) expression is correlated with a progressed stage of human tumors (Takenaga et al., 1997) . Its expression is also reverse correlated with the survival rates of the breast cancer patients (Rudland et al., 2000) . It was hypothesized that the Mts1(S100A4) protein participates in tumor progression and metastasis by aecting the motility of tumor cells (Kriajevska et al., 1994; Ford and Zain, 1995) .
The Mts1(S100A4) protein belongs to the S100 family of small Ca 2+ -binding proteins. The S100 family members are shown to be involved in a variety of physiological functions, such as cell proliferation and dierentiation, extracellular signal transduction, intercellular adhesion and cell motility (Schafer and Heizmann, 1996; Takenaga et al., 1994; Watanabe et al., 1993) . Some S100 proteins are secreted from dierent cell types stimulating neurite outgrowth, another in¯uence cell proliferation and induce apoptosis (Zimmer et al., 1995) . A number of S100 proteins exhibit both intra-and extra-cellular functions (Donato, 1999) . A number of targets, such as a heavy chain of non-muscle myosin and p53 were described for the Mts1 protein, suggesting its participation in the process of cell motility and proliferation (Kriajevska et al., 1994; Ford and Zain, 1995, Grigorian et al., 2001) . The Mts1(S100A4) protein is present in a solution in dierent oligomeric and dimeric conformations. It has been demonstrated that only oligomeric conformation of the protein is capable of stimulating the neurite outgrowth of the rat primary hippocampal neurons (Novitskaya et al., 2000) . These observations suggest that Mts1(S100A4) also might exhibit extra-and intracellular functions.
Despite the wide variety of functions oered for the Ca 2+ -binding proteins and also the variety of potential targets for them, the exact mechanism of their action remains unknown.
Neovascularization is important for a rapid growth and metastasis of solid tumors. The acquisition of an angiogenic phenotype is considered to be crucial for the tumor progression (Folkman et al., 1989; Gimbrone et al., 1972) . This phenomenon coincides with an increased entry of tumor cells into the circulation, thereby stimulating the tumor dissemination (Weidner, 1995 , Liotta et al., 1974 . Tumor angiogenesis notably mediates the tumor invasion into the adjacent stroma and thereby also facilitates metastasis (Skobe et al., 1997) .
Here we show that the Mts1(S100A4) protein may contribute to the tumor progression by in¯uencing the tumor angiogenesis via stimulation of the motility of endothelial cells.
Results

Analysis of hemangiomas in the HMGCR/mts1 transgenic mice
The ®rst indication on the possibility that Mts1(S100A4) could participate in tumor angiogenesis came from studies of pathological changes observed in aged HMGCR/mts1 transgenic mice. Strains of HMGCR/mts1 transgenic mice with the mts1(S100A4) gene under control of the ubiquitous promoter of 3-hydroxy-3-methylglutaryl CoA-reductase gene were characterized by a down-regulation of Mts1(S100A4) expression at the post-translational level (Ambartsumian et al., 1999) . The phenotype of the HMGCR/ mts1 mice was normal. An increased level of the mts1(S100A4) RNA was documented in all the organs tested, whereas the corresponding level of the protein was detected only in the organs normally expressing Mts1(S100A4).
Among pathological manifestations accumulated during ageing of the HMGCR/mts1 transgenic mice (17 ± 26 months) the most striking ones were tumor-like formations located mainly in the liver. A total of 11 (14%) tumors were developed in 78 aged animals from four dierent HMGCR/mts1 transgenic strains. Tumors were detected not only in the liver (n=9) ( Figure  1a ), but also in the spleen (n=1) and skin (n=1) of the animals. Lymphomas and lung adenomas were detected in approximately 10 ± 15% of transgenic and nontransgenic groups. Table 1 represents the incidence of hemangiomas and lymphomas in control and transgenic animals of dierent ages.
The histopathological analysis of the tumor-like formations demonstrated that they represent vascular tumors ± hemangiomas. We identi®ed cavernous hemangiomas (n=4), where the hepatocytes were lined by a single layer of endothelial cells (Figure 1b) and hemangiomas of the mixed type (n=6), consisted of large irregular vascular channels lined by¯attened, normal looking endothelial cells and of solid structures composed of sheets of endothelial cells (4 ± 10 cells) surrounding hepatic cords (Figure 1c ). Vascular spaces were ®lled with blood. Generally, benign tumors of vascular origin ± hemangiomas, are extremely rare in the populations of laboratory mice. The incidence of spontaneous hemangiomas in mice of dierent strains throughout their natural life ranges from 0.16% to 0.6% (Frith and Wiley, 1982; Peters et al., 1972; Booth and Sundberg, 1995) .
Liver hepatocytes in the nontransgenic animals did not express Mts1(S100A4). In the hepatocytes from the HMGCR/mts1 transgenic animals expression of the Mts1(S100A4) protein, but not the RNA, was largely repressed (Ambartsumian et al., 1999) . Immunohistostaining of liver hemangiomas with antibodies against Mts1(S100A4) demonstrated that the hepatocytes in the aected area expressed Mts1(S100A4), whereas the endothelial lining cells were negative for Mts1(S100A4) (Figure 1e ). Moreover, we observed an increase in the Mts1(S100A4) expression in hepatocytes surrounding the lesion (Figure 1d ). The unaected part of the liver did not contain Mts1(S100A4) positive hepatocytes ( Figure 1f ). This ®nding led us to an assumption that the tissue-speci®c down-regulation of translation observed in HMGCR/mts1 transgenic mice was altered in aged animals. Upon ageing, the strictness of repression could be deregulated in some animals, resulting in accumulation of the Mts1(S100A4) protein in dierent tissues, and, possibly, in blood with a subsequent development of pathological changes such as stimulating the development of vascular structures of hemangioma.
Detection of the Mts1(S100A4) protein in conditioned media and serum
Since the endothelial cells in hemangioma unlike the surrounding hepatocytes, did not express Mts1(S100A4) one could propose that Mts1(S100A4) might be secreted from the hepatocytes that overexpress the protein, or from some other unidenti®ed cells in the mouse organism, and either stimulate endothelial cells by itself, probably, in concert with the other angiogenic factors, or by interaction with their modulators.
To test this proposition, we ®rst attempted to immunoprecipitate the Mts1(S100A4) protein from the serum of transgenic and nontransgenic animals. This experiment revealed varying amounts of the protein in serum of dierent animals ( Figure 2a ). The level of the Mts1(S100A4) protein in the mouse serum was quanti®ed using sandwich ELISA. Comparison of the levels of the protein in serum of transgenic and nontransgenic animals of dierent ages revealed some dierences. It was found that 2 ± 16 month old transgenic animals contained 1.24 (P50.037) times more Mts1(S100A4) protein in the serum than their nontransgenic counterparts (Figure 2b , bars 1 and 3). Whereas the amount of Mts1(S100A4) in the serum of 17 ± 26 month old transgenic animals was 1.73 times higher (P50.02) than in the control animals of the same age (Figure 2b , bars 2 and 4). The data demonstrated that the Mts1(S100A4) protein was accumulated in the blood of ageing transgenic animals.
Secondly, we analysed the possibility of Mts1(S100A4) secretion. We attempted to immuno-precipitate the Mts1(S100A4) protein from the conditioned media collected from the Mts1(S100A4) expressing CSML100 cell line. Figure 3a demonstrates the accumulation of Mts1(S100A4) in the conditioned media at dierent time periods. A substantial amount of the protein was accumulated in 24 h. The speci®city of the anti-Mts1(S100A4) antibody used in these experiments was controlled by immunoprecipitation of Mts1(S100A4) from wild type or mts1(S100A4)7/7 ®broblasts followed by Western blot analysis ( Figure  3b , compare lanes 1 and 2).
Up to 20% of Mts1(S100A4) could be detected in the conditioned medium from the cells over-expressing the Mts1(S100A4) protein. The VMRLiv tumor cells transfected with the Mts1(S100A4) under control of tetracycline-inducible promoter successively accumulated Mts1(S100A4) in the conditioned medium after induction (Figure 3c ).
To analyse the conformational composition of the secreted protein we used the conditioned medium from the 35 S-labeled retrovirus-infected CSML0 cells overproducing the Mts1(S100A4) protein. It was collected and subjected to the size-exclusion chromatography. The distribution of the Mts1(S100A4) speci®c protein in the column was compared to the recombinant Mts1(S100A4) (Figure 3d ). The Mts1(S100A4) protein was detected in the fractions that corresponded not only to dimeric, but also to the heavy, oligomeric, protein. Although the fraction of the oligomers was not so abundant compared to the recombinant protein (Figure 3d ), this ®nding indicated that the oligomeric Mts1(S100A4) is formed in vivo and is not a result of the arti®cial conditions of the protein overproduction in the bacterial cells.
Moreover, we performed the size-exclusion chromatography of human plasma of cancer patients that contained high amounts of the Mts1(S100A4) protein. Figure 3e presents the sandwich ELISA analysis of the fractionated plasma. Distribution of the Mts1(S100A4) 
Oncogene Mts1(S100A4) protein is an angiogenic factor N Ambartsumian et al protein from the plasma was compared to distribution of the recombinant Mts1(S100A4) protein. The Mts1(S100A4) ± speci®c immunoreactivity was revealed in the fractions corresponding to both dimeric and oligomeric forms.
Mts1(S100A4) stimulates motility of the endothelial cells in vitro
We examined the possibility whether the oligomeric Mts1(S100A4) was able to in¯uence the behavior of the endothelial cells in vitro and in vivo. We ®rst measured nondirectional motility of endothelial cells stimulated by the Mts1(S100A4) protein. Dose-dependent stimulation of the undirected motility of endothelial cells was observed ( Figure 4a ). The mean-square-speed of the cells at the concentration of 0.5 mM of Mts1(S100A4) increased by 24% as compared to the controls. For a more detailed analysis of the in¯uence of Mts1(S100A4) on the motile behavior of SVEC4-10 cells, the data were expressed as the mean-square-displacement of the cells (d 2 ), at time t and ®tted to the equation describing single cell motility ( Figure 4b ). Treatment of the cells with 0.5 mM Mts1(S100A4) caused a factor 1.3 increase of the root mean square speed (S) and a 1.45 times increase of diusion rate (R), but did not aect the persistence time (P). This observation indicates that the impact of Mts1(S100A4) on the motility of the cells occurs due to an increase of the cell speed rather than to a change in the persistence time.
When the oligomeric and dimeric forms were used in the same test it has been revealed that only the oligomeric Mts1(S100A4) stimulated nondirectional motility with an optimal concentration of 0.05 mM. The stimulation of motility was higher than the one of bFGF (basic ®broblast growth factor) and comparable with HGF (hepatocyte growth factor) and was blocked by an addition of the anti-Mts1(S100A4) antibodies. The Y75F inactive mutant form of the Mts1(S100A4) had no eect on the motility of SVEC4-10 cells as well (Novitskaya et al., 2000) ( Figure 4c ). Testing the possible synergy between Mts1(S100A4) and bFGF indicated that these two factors did not act synergistically in stimulation of nondirectional motility of endothelial cells (data not shown).
We also tested the cell speci®city of stimulation of movement induced by Mts1(S100A4). As it is shown in Figure 4D the observed eect was speci®c for the endothelial cells we used in our experiments. Mts1(S100A4) had no eect on mouse ®broblasts and CSML0 cell line.
The oligomeric Mts1(S100A4) stimulated the migration of the SVEC4-10 cells in a modi®ed Boyden chamber assay in a dose-dependent manner ( Figure  5a ). The checkerboard analysis indicated that this stimulation was chemotactic rather than chemokinetic by nature (Taraboletti et al., 1987) (Figure 5b) . However, the values along the diagonal indicating a random motility also increase 1.5+0.28 times, which coincides with the data obtained from the measurements of individual cell motility.
Mts1(S100A4) induces angiogenic response in vivo
To con®rm the hypothesis, that Mts1(S100A4) is capable of stimulating angiogenesis, we analysed the ability of puri®ed protein to induce angiogenic response in vivo.
Micropellets of aluminum sulphate coated with the slow release polymer-hydron containing oligomeric and dimeric forms of the Mts1(S100A4) protein as well as VEGF were implanted into the corneas of C57B16/J mice. Neovascularization and dilation of limbal vessels of mouse corneas was observed mainly by oligomeric form of Mts1(S100A4) and to much lesser extent by the dimeric one. The results of the mouse corneal micropocket assay are presented in Figure 6 . The measured microvessel length, clockhours and area were large in the corneas implanted with pellets containing the oligomeric fraction of the Mts1(S100A4) protein (Figure 6a ± c) . The corresponding eect in the case of the dimeric form of the protein was substantially smaller. The pellets containing recombinant myosin fragment did not induce corneal neovascularization. (1,2) and nontransgenic (4,5) mice using the anti-Mts1(S100A4) antibodies. 3-immunoprecipitation with the normal rabbit serum as a negative control. (b) Amount of Mts1(S100A4) in mouse serum determined by sandwich ELISA; 1-nontransgenic animals 2 ± 16 months old (n=17), 2-nontransgenic animals 17 ± 26 months old (n=5); 3-transgenic animals 2 ± 16 months old (n=5), 4-transgenic animals 17 ± 26 months old (n=10). Bars represent means+s.d.
Vascularization of the mammary tumors expressing Mts1(S100A4)
Our studies of the angiogenic activity of the Mts1(S100A4) protein led us to a conjecture that Mts1(S100A4) might contribute to the tumor metastasis by enhancing the tumor vascularization.
We thus compared the levels of vascularization of mammary tumors induced in the GRS/A nontransgenic mice and GRS/A-mts1 hybrid transgenic mice that overexpress mts1(S100A4) in the mammary gland. Mammary tumors of the GRS/A mice normally do not metastasize. Forty per cent of the tumors generated in the GRS/A-mts1 hybrid transgenic mice metastasize to the lungs (Ambartsumian et al., 1996) .
The vessel density was determined in the dierent randomly selected areas of transgenic and nontransgenic tumors. Sections of the tumors were stained for the mouse endothelial cell marker7 CD31. Table 2 shows the comparison of the mean values of the vessel density in 10 transgenic and 10 nontransgenic tumors. The mean vessel density in the transgenic tumors expressing Mts1(S100A4) protein was 1.5 times higher than in the nontransgenic ones (P50.024).
Discussion
The early studies of the tumor angiogenesis de®ned its crucial role for a continued development of the tumor (Folkman, 1971) . Angiogenesis is also a critical component of the tumor metastasis. Increased microvessel density is regarded as a signi®cant and independent prognostic indicator in a number of human cancers (Ellis and Fidler, 1996) .
Number of factors stimulating and inhibiting the process of tumor angiogenesis was discovered (Zetter, 1998) . Therapeutic approaches based on inhibition of angiogenesis by gene therapy were utilized in mice leading to inhibition of growth of primary tumor and corresponding metastases (Lin et al., 1998; Goldman et al., 1998) .
The mts1(S100A4) gene was strongly associated with the tumor progression and promotion of metastases. The mechanism of its action in tumor progression although remained obscure.
In this work we analysed the metastasis promoting function of Mts1(S100A4) associated with its extracellular activity that manifests itself in stimulation of motility of endothelial cells and, as a result, in enhanced tumor vascularization.
An extracellular function has been reported for a number of S100 proteins. Extracellular S100b has been shown to induce neurite extension (Kligman and Hilt, 1988; Winningham-Major et al., 1989) , whereas S100A2, S100A7 and S100A8 and S100A9 demonstrate chemoattractive function (Komada et al., 1996; Jinquan et al., 1996; Geszy, 1996) . The Mts1(S100A4) protein, as was demonstrated previously, could be secreted from rat ®broblasts and bovine aorta smooth muscle cells (Watanabe et al., 1992) . Recently, an inhibition of mineralization was suggested as a function for the Mts1(S100A4) protein secreted from the periodontal ligament cells (Duarte et al., 1999) . Extracellular Mts1(S100A4) also stimulated neurite outgrowth from rat hypocampal neurons (Novitskaya et al., 2000) . As we show here Mts1(S100A4) could be released from tumour cells. Moreover, exogenously added Mts1(S100A4) is capable to induce angiogenesis in vivo and aected motility of endothelial cells in vitro. The angiogenic activity of the Mts1(S100A4) protein is attributed to the oligomeric and not the dimeric form of the protein. This correlates with data obtained from the analysis of the neuritogenic activity of the Mts1(S100A4) protein (Novitskaya et al., 2000) . The Mts1(S100A4) oligomer is detected in vivo in the conditioned media of the cells over-expressing the Mts1(S100A4) protein as well as human plasma. Association of the functional activity with the multimeric form of the Mts1(S100A4) protein distinguishes it from the other S100 proteins for which the functional activity is attributed to a dimer (Donato, 1999) .
The non-fractionated Mts1(S100A4) protein exhibited its angiogenic activity at a rather high concentration ± 5 mg/ml. The well-known angiogenic factors act at much lower concentrations 1 ± 10 ng/ml . The optimal concentration of the physiologically active Mts1(S100A4) oligomer was 10 times less (500 ng/ml) than that for the non-fractionated one. Moreover, since the oligomeric fraction is a mixture of dierent conformations of the Mts1(S100A4) protein (hexamers, dodecamers etc.), we suppose that thè active' conformation constitute notably only part of the oligomeric fraction of the protein.
Mts1(S100A4) is detected in the normal mouse serum in an average concentration of 40 ± 60 ng/ml. Aged HMGCR/mts1 transgenic animals, as we demonstrated here, contain 100 ± 120 ng/ml of the protein in the serum. Moreover, the Mts1(S100A4) expressing tumor bearing animals contain an increased amount of the protein in the serum (our unpublished data). So, the amount of Mts1(S100A4) detected in the mouse serum is much higher than the one characteristic for the typical angiogenic factors.
Measurements of the vascular density of the tumors expressing the Mts1(S100A4) protein demonstrated an enhancement of this parameter. Thus, we can suggest that the Mts1(S100A4) protein acts as a stimulator or co-stimulator of angiogenesis and consequently induces the tumor progression and metastasis formation.
The most probable scenario for the angiogenic activity of Mts1(S100A4) is that it acts in concert with the other angiogenic factors, or even by forming a physical complex with some of them. It has been shown, for example, that S100A13 is associated with FGF-1 in vivo and may be involved in the regulation of FGF-1 release (Carreira et al., 1998) . However, our preliminary experiments with bFGF(FGF-2) which is considered as a potent angiogenic factor did not reveal synergistic action of these two factors, neither were we able to document activation of expression of bFGF in response to Mts1(S100A4) treatment of the cells (our unpublished data).
In the developing tumor not only the tumor cells by themselves could secrete Mts1(S100A4). Analysis of mouse mammary tumors demonstrated that certain cells in the stroma presumably tumor ®broblasts or macrophages express high levels of the Mts1(S100A4) protein (Ambartsumian et al., 1996) . It was demonstrated that the cultured rat ®broblasts could secrete the Mts1(S100A4) protein (Watanabe et al., 1992) . The activated macrophages that are regarded as cells producing angio-stimulatory and angio-inhibitory molecules (Polverini, 1996) also express Mts1(S100A4) Oncogene Mts1(S100A4) protein is an angiogenic factor N Ambartsumian et al . One can suppose that Mts1(S100A4) expression and release is activated upon recruiting of the macrophages into the tumor and their switch to the tumor phenotype.
There are certain well-distinguished stages of angiogenesis that include a degradation of the basement membrane, movement of the endothelial cells towards the angiogenic stimuli, their proliferation and ®nally the capillary formation. Data obtained in in vitro experiments indicate that, when applied exogenously, Mts1(S100A4) stimulates the motility of the endothelial cells rather than their proliferation. This distinguishes Mts1(S100A4) from the other well-known angiogenic factors that, as a rule, stimulate the cell proliferation. Based on our results we propose that Mts1(S100A4) acts as a motility stimulating, rather than proliferation factor. This again indicates, that Mts1(S100A4) should act in association with another angiogenic factors to achieve a full angiogenic response.
Mts1(S100A4) stimulates motility of endothelial cells in a cell-speci®c manner, it does not aect motility of mammary carcinoma cells or mouse ®broblasts. This observation may indicate that Mts1(S100A4) recognizes a speci®c receptor on the surface of the endothelial cell.
The bell-shaped appearance of the dose-response curves, the chemotactic activity in Boyden chamber assay as well as the ability of insoluble Mts1(S100A4) to stimulate neurite outgrowth (Novitskaya et al., 2000) also refers to a receptor-mediated mechanism of the Mts1(S100A4) action.
Recently the receptor for advanced glycation end products (RAGE) located on the surface of human umbilical vein endothelial cells (HUVEC) was shown to be utilized by two members of the S100 family proteins (Hofmann et al., 1999) .
Materials and methods
Cell lines
Mouse endothelial SVEC4-10 cell line obtained from the American Type Culture Collection (ATCC). Mouse mammary adenocarcinoma cell lines: CSML-100 and VMR-liv (Senin et al., 1984) were derived from two independent spontaneous tumors in A/Sn mice. Conventional tetracycline-inducible clones of VMR-liv cells bearing mts1(S100A4) gene were obtained according to the protocols (Gossen and Bujard, 1992; Gossen et al., 1995) . CSML0 cell line was infected with a retroviral vector pMV-7 containing mts1 cDNA (pMV-mts1). Mts1 cDNA (Ebralidze et al., 1989) was cloned into HindIII and EcoR1 sites of the pMV-7 vector. Packaging cells GPE-86 (Markovitz et al., 1988) were transfected with pMV-mts1 plasmid or with an empty vector, neo-resistant clones were selected to obtain virus-producing cell line. Supernatants, containing virus were applied to CSML0 cells. Neomycin-resistant population of CSML0 cells was collected after 10 ± 14 week selection and used for further experiments. The resulting cells were referred as CSML0-mts1.
Purification and fractionation of proteins
Fragments encoding mouse Mts1(S100 A4), mutant containing a single tyrosine change (Y75F) and S100A12 proteins were cloned in the pQE30 expression vector (Qiagen, USA) and puri®ed according to the protocol of the manufacturer. The recombinant Mts1 protein, samples of human plasma and conditioned medium were fractionated by size exclusion chromatography on Superdex 75 column (1.5 cm 2 690.0 cm). Column was equilibrated with a buer 50 mM Tris-HCl, 150 mM NaCl, 1 mM 1,4 dithiotreitol, pH 7.5. The column was calibrated for molecular weight determination using Gel Filtration Chromatography Standards (Bio-Rad Laboratories, Hercules, CA, USA). 1 ml samples were loaded on the column and 3 ml fractions were collected and monitored with OD 280 readings. When required, fractions were analysed as described below.
Analysis of transgenic animals
HMGCR/mts1 transgenic mice were previously described (Ambartsumian et al., 1999) . Groups of transgenic and nontransgenic animals were kept for up to 26 months. Animals with signs of disease were sacri®ced and subjected to histopathological analysis. Sections stained with hematoxilineosin were used for histopathological analysis. Immunohistostaining with anity puri®ed rabbit anti-Mts1(S100A4) antibodies was performed as described (Ambartsumian et al., 1996) . The speci®city of the antibodies was tested by immunostaining of tissue preparations obtained from the Mts1(7/7) mice. The Mts1(S100A4)(7/7) mice were obtained by deletion of the entire coding region of the mts1(S100A4) gene. mts1(S100A4) speci®c RNA was not detected in the organs of 7/7 mice. (Ambartsumian et al., 2001, in preparation) .
Sandwich ELISA assay for the Mts1(S100A4) protein Enzyme-linked immunosorbent assay (sandwich ELISA) was used for determination of Mts1(S100A4) content in the mouse serum. Nunc-Immuno Maxisorp 96 well plates (Life technologies) were coated with 5 mg/ml of anti-S100A4(mts1) mouse monoclonal antibodies ± HM4 (Kriajevska et al., 1994) . Mouse serum was added in dilution 1 : 20 in 5% BSA and incubated for 1 h at room temperature. Second antibody was 2 mg of anity puri®ed rabbit anti-Mts1(S100A4) (Ambartsumian et al., 1996) . The formed complexes were visualized by sequential incubation with horseradish peroxidase coupled goat ant-rabbit IgG and OPD chromogenic substrate (DAKO A/S, Denmark). The reaction was quanti®ed on ELISA reader. The sensitivity of reaction was less than 20 ng/ml. Serum from the Mts1(S100A4)7/7 mice was used as a negative control in these experiments.
Mouse monoclonal 129 antibodies against human Mts1(S100A4) protein (Kriajevska et al., 1994) were used in sandwich ELISA assay for determination of the Mts1(S100A4) content in human plasma.
Immunoprecipitation and Western-blot analysis of Mts1(S100A4)
Prior to the immunoprecipitation cell extracts were prepared in 16RIPA buer with protease inhibitors (150 mM NaCl, 1.0% NP-40, 0.5% DOC, 0.1% SDS, 50 mM Tris pH 8.0, 1 mM DTT, 10 mg/ml leupeptin, 2 mg/ml aprotinin, 0.1 mM PMSF and 1 mM benzamidin). Conditioned medium for immunprecipitation was adjusted to 16RIPA. Mouse serum prior to the immunoprecipitation was diluted 10 times in 16RIPA buer with protease inhibitors.
Samples from the size exclusion chromatography were also adjusted to 16RIPA buer. Anti-Mts1(S100A4) rabbit serum was used for immunoprecipitation followed by adsorption of the complexes on protein G Sepharose (Pharmacia, Sweden). Normal rabbit serum was used as a negative control to the immunoprecipitation. The speci®city of immunoprecipitation was tested by precipitating extracts of primary mouse embryo ®broblasts derived from the Mts1(S100A4)7/7 mice (Ambartsumian et al., 2001, in preparation) .
Samples were separated by 15% SDS-polyacrilamide gel (PAAG) electrophoresis under reducing conditions, transferred by electro-blotting on Immobilon P membrane (Millipore, USA). Speci®c bands were visualized by sequential incubation of the ®lters with anity puri®ed polyclonal rabbit anti-Mts1(S100A4) antibodies horseradish peroxidase coupled goat anti-rabbit antibodies (Dako A/S) and ECL substrate (Amersham, USA).
Mouse corneal micropocket assay
Mouse corneal micropocket assay was performed according to procedure previously described (Cao et al., 1995 (Cao et al., , 1998 . A micropellet (0.3560.35 mm) of sucrose aluminum sulfate (Bukh Meditec, Copenhagen, Denmark) coated with hydron polymer type NCC (IFN Sciences, New Brunswick, NJ, USA) containing 320 ng of Mts1(S100A4) protein or oligomeric and dimeric fractions of Mts1(S100A4) was implanted into each pocket. 320 ng of recombinant myosin was used as a negative control, and 160 ng of recombinant human VEGF as a positive control. The corneal neovascularization was examined on day 5 after implantation. Ten corneas of ®ve mice were used in each group.
Random cell motility assay SVEC4-10, L9 or CSML0 cultures were seeded in six-well tissue culture plates (35 mm diameter wells) at a density of 3610 3 cells/cm 2 , and incubated for 24 h before video recording. One hour before analysis culture medium was changed and the recombinant Mts1(S100A4) or other proteins were added. Time-lapse video recording was done as previously described (Kustikova et al., 1998) .
Individual cell motility was determined as described (Walmod et al., 1998) . From the length of individual cell tracks the cell displacement, d, was determined and the mean cell speed at a time interval, t, of 10 min was calculated as S 10 =d/t (Dunn, 1983) . Data also were expressed as the mean-square-displacement of the cells (d 2 ) in relation to t, and ®tted to the equation describing individual cell motility as a persistent random walk (Walmod et al., 1998) 
where S (distance/time) stands for the theoretical root-meansquare speed, P (time) ± persistence time of direction. Also the rate of diusion, R (distance 2 /time) was calculated, R being equal to 2S 2 P.
Boyden chamber assay
Boyden chamber assay was performed essentially as described (Taraboletti et al., 1987) . Filters were coated with 20 mg/ml ®bronectin. 2610 5 SVEC4-10 cells were propagated in DME-F12(1 : 1) supplemented with 1% FCS for 5 h. Basal migration was determined using a range of concentrations of BSA and the average number of cells moved through the ®lter was de®ned as motility index equal to 1. All the results are a mean from two independent experiments performed in triplicate.
Determination of the Mts1(S100A4) release from the cells CSML100 cells were grown to subcon¯uency fresh media was then added and conditioned media was collected at dierent periods of time. The supernatants were collected, ®ltered through nitrocellulose ®lters 0.45 m (Millipore, USA), Mts1(S100A4) protein was immunoprecipitated and detected by Western blot analysis as described.
Cells of VMR-liv (tet-on) clone 137.188 were treated with 2 mg/ml doxycillin for 24 h for mts1(S100A4) activation. After induction cells were metabolically labeled for 2 h in methionine7cystein-free medium supplemented with dialyzed and inactivated 10% FCS with 0.2 mCi/ml [ 35 S]-methionine and 7cystein (ICE, England). After labeling the cells were washed and fresh conventional media was added and the cells were incubated for dierent periods of time. The supernatants were collected, ®ltered and Mts1(S100A4) protein was immunoprecipitated as described followed by Westernblot analysis. To quantify the intensity of the 35 S-labelled bands, the ®lters were scanned after exposition by using a Molecular Dynamics computing densitometer with ImageQuant software.
CSML0-mts1 cells were metabolicaly labeled for 3 h in methionine7cystein-free medium supplemented with dialyzed and inactivated 10% FCS with 0.2 mCi/ml [ 35 S]-methionine and 7cystein (ICE, England). After labeling the cells were washed and fresh conventional media was added and the cells were incubated for 24 h for optimal Mts1(S100A4) release. Conditioned media was collected and subjected to size exclusion chromatography as described before. Samples from the fractions were immunoprecipitated and separated by 4 ± 20% gradient PAAG under reducing conditions. To quantify the intensities of the bands, the gels were scanned after exposition by using a Molecular Dynamics computing densitometer with ImageQuant software.
Viability of the cells was determined by measuring lactate dehydrogenase activity in the media. Assay was performed according to the protocol of the manufacturer (Sigma, USA). Viability was found to be higher than 98% in all the experiments. All the experiments were reproduced twice.
Blood vessel density measurement
Frozen sections of the tumors extracted from the GRS/Amts1 hybrid and nontransgenic GRS/A tumor bearing females (Ambartsumian et al., 1996) were used for immunohistochemical staining with the CD31(PECAM-1) rat monoclonal antibodies (PharmInGen, USA) according to the protocol of manufacturer. The blood vessel density was determined as described (Ferrara et al., 1998) . Vessel density of 40 random ®elds of 10 tumors in each group was determined. Two-tailed Students distribution was used for statistical analysis.
